apixaban trial summary

Acute coronary syndrome

All ACS (including AMI): 4 trials - APPRAISE-1 (10mg od) - APPRAISE-1 (2.5 mg bid) - APPRAISE 2 - APPRAISE japan

No demonstrated result

major or minor bleeding by 174% (harmful effect)

any bleedings by 121% (harmful effect)

major or clinically relevant non-major bleeding by 139% (harmful effect)

Major bleeding by 153% (harmful effect)

See more clinical conditions

All type of patients: 4 trials - APPRAISE-1 (10mg od) - APPRAISE-1 (2.5 mg bid) - APPRAISE 2 - APPRAISE japan

No demonstrated result

major or minor bleeding by 174% (harmful effect)

any bleedings by 121% (harmful effect)

major or clinically relevant non-major bleeding by 139% (harmful effect)

Major bleeding by 153% (harmful effect)

Patients with a recent ACS: 4 trials - APPRAISE-1 (10mg od) - APPRAISE-1 (2.5 mg bid) - APPRAISE 2 - APPRAISE japan

No demonstrated result

major or minor bleeding by 174% (harmful effect)

any bleedings by 121% (harmful effect)

major or clinically relevant non-major bleeding by 139% (harmful effect)

Major bleeding by 153% (harmful effect)

Atrial fibrillation

All type of patients : 3 trials - ARISTOTLE - AVERROES - phase 2 apixaban

No demonstrated result

suggested thrombo-embolic event (cerebral or systemic) by 54% (not demonstrated)

suggested ischemic stroke by 63% (not demonstrated)

suggested stroke (fatal and non fatal) by 54% (not demonstrated)

thrombo-embolic event (cerebral or systemic) by 20% (fully demonstrated)

Major bleeding by 30% (fully demonstrated)

All cause death by 11% (fully demonstrated)

suggested major or clinically relevant non-major bleeding by 30% (not demonstrated)

suggested Haemmorhagic stroke by 49% (not demonstrated)

suggested stroke (fatal and non fatal) by 21% (not demonstrated)

See more clinical conditions

Patients ineligible for warfarin: 1 trials - AVERROES

No demonstrated result

suggested thrombo-embolic event (cerebral or systemic) by 54% (not demonstrated)

suggested ischemic stroke by 63% (not demonstrated)

suggested stroke (fatal and non fatal) by 54% (not demonstrated)

Primary prevention of thromboembolic events: 3 trials - ARISTOTLE - AVERROES - phase 2 apixaban

No demonstrated result

suggested thrombo-embolic event (cerebral or systemic) by 54% (not demonstrated)

suggested ischemic stroke by 63% (not demonstrated)

suggested stroke (fatal and non fatal) by 54% (not demonstrated)

thrombo-embolic event (cerebral or systemic) by 20% (fully demonstrated)

Major bleeding by 30% (fully demonstrated)

All cause death by 11% (fully demonstrated)

suggested major or clinically relevant non-major bleeding by 30% (not demonstrated)

suggested Haemmorhagic stroke by 49% (not demonstrated)

suggested stroke (fatal and non fatal) by 21% (not demonstrated)

Pulmonary embolism

All type of patients: 3 trials - AMPLIFY - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg

No demonstrated result

suggested Major bleeding by 69% (not demonstrated)

No demonstrated result

suggested VTE by 67% (not demonstrated)

No demonstrated result

suggested VTE by 64% (not demonstrated)

Thrombosis prevention

elective major knee surgery : 3 trials - APROPOS 2.5mg - ADVANCE-1 - ADVANCE 2

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 50% (not demonstrated)

suggested Deep vein thrombosis by 40% (not demonstrated)

suggested total VTE and all-cause mortality by 38% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major or clinically relevant non-major bleeding by 33% (not demonstrated)

See more clinical conditions

All type of patients : 4 trials - APROPOS 2.5mg - ADVANCE-1 - ADVANCE 3 - ADVANCE 2

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 60% (not demonstrated)

suggested Deep vein thrombosis by 68% (not demonstrated)

suggested total VTE and all-cause mortality by 64% (not demonstrated)

suggested asymptomatic DVT by 67% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 50% (not demonstrated)

suggested Deep vein thrombosis by 40% (not demonstrated)

suggested total VTE and all-cause mortality by 38% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major or clinically relevant non-major bleeding by 33% (not demonstrated)

Elective hip replacement: 1 trials - ADVANCE 3

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 60% (not demonstrated)

suggested Deep vein thrombosis by 68% (not demonstrated)

suggested total VTE and all-cause mortality by 64% (not demonstrated)

suggested asymptomatic DVT by 67% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

Elective major knee surgery : 2 trials - APROPOS 2.5mg - ADVANCE 2

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 50% (not demonstrated)

suggested Deep vein thrombosis by 40% (not demonstrated)

suggested total VTE and all-cause mortality by 38% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

Medical patients: 1 trials - ADOPT

No demonstrated result

suggested Symptomatic deep-vein thrombosis by 69% (not demonstrated)

Orthopaedic surgery: 4 trials - APROPOS 2.5mg - ADVANCE-1 - ADVANCE 3 - ADVANCE 2

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 60% (not demonstrated)

suggested Deep vein thrombosis by 68% (not demonstrated)

suggested total VTE and all-cause mortality by 64% (not demonstrated)

suggested asymptomatic DVT by 67% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 50% (not demonstrated)

suggested Deep vein thrombosis by 40% (not demonstrated)

suggested total VTE and all-cause mortality by 38% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major or clinically relevant non-major bleeding by 33% (not demonstrated)

Orthopedic surgery : 4 trials - APROPOS 2.5mg - ADVANCE-1 - ADVANCE 3 - ADVANCE 2

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 60% (not demonstrated)

suggested Deep vein thrombosis by 68% (not demonstrated)

suggested total VTE and all-cause mortality by 64% (not demonstrated)

suggested asymptomatic DVT by 67% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major VTE (fatal and non fatal DVT,PE) by 50% (not demonstrated)

suggested Deep vein thrombosis by 40% (not demonstrated)

suggested total VTE and all-cause mortality by 38% (not demonstrated)

suggested proximal DVT by 65% (not demonstrated)

No demonstrated result

suggested major or clinically relevant non-major bleeding by 33% (not demonstrated)

Patients with cancer: 1 trials - CV185-027

No demonstrated result

Venous thrombosis

secondary prevention of VTE : 2 trials - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg

No demonstrated result

suggested VTE by 67% (not demonstrated)

No demonstrated result

suggested VTE by 64% (not demonstrated)

See more clinical conditions

All type of patients: 4 trials - Botticelli DVT - AMPLIFY - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg

No demonstrated result

suggested Major bleeding by 69% (not demonstrated)

No demonstrated result

suggested VTE by 67% (not demonstrated)

No demonstrated result

suggested VTE by 64% (not demonstrated)

All types of patients: 4 trials - Botticelli DVT - AMPLIFY - AMPLIFY-EXT 2.5mg - AMPLIFY-EXT 5mg

No demonstrated result

suggested Major bleeding by 69% (not demonstrated)

No demonstrated result

suggested VTE by 67% (not demonstrated)

No demonstrated result

suggested VTE by 64% (not demonstrated)

Patients with cancer: 2 trials - CAP - CARAVAGGIO

No demonstrated result

Apixaban antithrombotics

Eliquis - BMS-562247 - BMS562247 - BMS 562247

Acute coronary syndrome

Atrial fibrillation

Pulmonary embolism

Thrombosis prevention

Venous thrombosis